New Republic Capital’s Ascendis Pharma A/S ASND Stock Holding History

New Republic Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.68M	Buy	+6,286	New	+$1.47M	0.39%	53

Other funds holding ASND

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

BSA

Braun Stacey Associates New York $3.53B AUM 63.32% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return

New Republic Capital's ASND Position: Q2 2026 in Review

New Republic Capital opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 6,286 shares worth $1.68M. The stake represents 0.39% of the portfolio and ranks #53 among its holdings.

88 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

New Republic Capital held 6,286 shares of Ascendis Pharma A/S worth $1.68M as of Q2 2026.
Ascendis Pharma A/S was a new New Republic Capital position in Q2 2026.
Ascendis Pharma A/S made up 0.39% of New Republic Capital's portfolio in Q2 2026, its #53 holding.
88 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on New Republic Capital's 13F filing for Q2 2026, filed 31 Jul 2026.